Baclofen
β-(4-chlorophenyl)-γ-aminobutyric acid
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Baclofen is a synthetic depressant of the GABA structural analog class.[1] It is a modified form of GABA — the brain's main calming signal — built to cross the blood-brain barrier. It activates GABA receptors, quieting nerve activity and producing muscle relaxation and sedation.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
GHB, GBL, phenibut +1 moreGHB, GBL, phenibut, other GABA-B active agents show less
Synthesized in 1962 as an experimental anti-seizure drug, it failed that purpose but revealed strong muscle-relaxing effects.[1] In 2005, Olivier Ameisen published a self-case report describing complete suppression of alcohol dependence at doses up to 270 mg/day.[3] France formally approved baclofen for alcohol use disorder in 2020, the first country to do so.[4]
Subjective effects include muscle relaxation, sedation, reduced anxiety, and cognitive slowing.[5] The experience is defined by a flat, clean calm — tension dissolves without the warmth or euphoria of alcohol or benzodiazepines. Drowsiness, cognitive fatigue, and impaired coordination are common unsought effects, intensifying at higher doses.
Baclofen produces physical dependence with regular use,[6] and overdose can cause respiratory failure and fixed pupils that mimic brain death.[7][8] Kidney function is the key variable — the drug exits unchanged through the kidneys,[9] so impaired kidneys allow dangerous accumulation. Fifty years of clinical use provide substantial safety data, though a human lethal dose remains unestablished.
History[edit]
Discovery
Baclofen was synthesized in 1962 by Heinrich Keberle at Ciba-Geigy, following research interest in making GABA-like molecules that could cross into the brain.[1][10] The design attached a chlorinated ring to GABA, making the molecule fat-soluble enough to pass the blood-brain barrier. It failed as an anti-seizure drug but proved effective at reducing muscle spasticity, so development shifted entirely.[10]
Clinical Adoption
The FDA approved baclofen in 1977 under the brand name Lioresal for spasticity in multiple sclerosis and spinal cord injury[1] — three years before its molecular target was formally identified. By the early 1980s, intrathecal delivery was developed: implanted pumps that deliver the drug directly into spinal fluid for patients who don't respond to oral treatment.[11]
Baclofen and Alcohol Use Disorder
In 2005, Olivier Ameisen published a self-case report describing complete suppression of alcohol dependence at doses up to 270 mg/day.[3] The account sparked a public movement and a 2014 French ruling permitting doses up to 300 mg/day.[12] France formally approved baclofen for alcohol use disorder as Baclocur in 2020, capping the approved dose at 80 mg/day.[4]
Chemistry[edit]
Structural Class
Baclofen is a GABA structural analog — built on the same amino acid backbone as GABA, the brain's primary calming chemical, with a chlorine-bearing ring attached to one end.[1] That ring makes the molecule fat-soluble enough to cross the blood-brain barrier, which natural GABA cannot do.[13][1]
| Molecular formula | C₁₀H₁₂ClNO₂ |
| Molecular weight | 213.66 g/mol |
Stereochemistry
The commercial drug is a racemate — an equal mix of two mirror-image molecules. The R-enantiomer (arbaclofen) carries essentially all the pharmacological activity; the S-form is inactive at GABA-B receptors.[1][14] Arbaclofen placarbil, a prodrug of the R-form designed for better absorption, has been studied in clinical trials for autism spectrum disorder and fragile X syndrome.[1]
Pharmacology[edit]
Mechanism of Action
Baclofen is the only FDA-approved selective GABA-B receptor agonist.[1] At nerve terminals in the spinal cord, it reduces the release of excitatory chemicals — particularly glutamate — quieting the overactivated pathways responsible for spasticity.[15][16]
In the brain's reward circuits, baclofen suppresses dopamine release.[17] This blunts the motivational drive toward alcohol and other substances, explaining both its anti-craving effect and its low potential for producing euphoria or addiction.
Pharmacokinetics
Baclofen is well absorbed orally, peaking in the bloodstream around 2 hours[18][13] with a half-life of about 3.5 hours.[13] The liver barely processes it — 65–70% exits the body unchanged through the kidneys.[18][9] Impaired kidney function causes accumulation and toxicity at standard doses.[9][19]
Neuroscience[edit]
Where It Acts
Baclofen's anti-craving effect originates in midbrain dopamine neurons — GABA-B activation there suppresses dopamine release into the brain's reward center.[17] Neuroimaging confirms this: baclofen reduces brain reactivity to alcohol-related cues in craving and emotion regions.[20][21] In the spinal cord, similar receptor activation at sensory terminals reduces the overactivated signals that cause spasticity.[15]
Why It Matters
Baclofen targets the motivational pull toward alcohol — the craving — without making drinking feel aversive. Patients stop reaching for alcohol without experiencing its absence as deprivation. It also lowers stress hormone (cortisol) levels in alcohol-dependent patients,[22] providing anxiety relief that may reduce stress-driven relapse.
The dose-response relationship for anti-craving efficacy versus adverse effects remains incompletely mapped. French data support doses above 80 mg/day,[12] but formal approval caps there.[4] Specific binding affinity values at GABA-B receptors have never been published — an unusual gap for a drug with over fifty years of clinical use.
Subjective Effects[edit]
Baclofen's experience is defined by muscular quieting rather than mental alteration. Tension releases and anxiety lifts, while thinking stays relatively clear at low doses. As doses increase, sedation deepens and cognition slows, moving toward a heavier state of psychomotor sluggishness and memory gaps.
Compared to GHB, baclofen produces far less euphoria and social warmth, consistent with its low abuse liability.[5] Relative to benzodiazepines, its cognitive effects are less amnestic at comparable sedation levels — though this distinction narrows at higher doses. It sits closer to a quiet off-switch than to the chemical ease of alcohol.
Effect Grid
At 20–50 mg oral, baclofen produces pronounced muscle relaxation, moderate sedation, and clear anxiolysis. Cognitive fatigue becomes apparent — thought deceleration is noticeable, and concentration requires more effort than usual. The mental state is quiet rather than intoxicated; there is no euphoric warmth or affective enhancement.
Physically, dizziness is common, nausea may occur, and motor control impairment becomes a practical concern. Pain suppression is noticeable. Some individuals report increased urination or mild gastrointestinal effects.
This range covers standard spasticity dosing and the lower end of alcohol use disorder treatment. Driving and operating machinery should be avoided. Doses are per-administration, not daily totals.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
External hallucinations
Physical fatigue · Bodily heaviness · Pain suppression · Nausea · Body high · Constipation · Dry mouth · Headache · Brain zaps · Breathing alteration · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Temperature dysregulation · Bodily dissociation
Nausea · Body high · Constipation · Dry mouth · Headache · Brain zaps · Breathing alteration · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vomiting · Bodily dissociation
Confusion · Language suppression · Memory suppression · Thought disorganization · Amnesia · Delirium
Thought disorganization · Delirium
Timeline
Initial awareness of muscular softening begins. A subtle calming may be perceptible, though effects are sub-threshold for most individuals.
Muscle relaxation deepens progressively. Mild sedation and emerging anxiolysis become noticeable. Slight dizziness or nausea may appear.
Maximum muscle relaxation, peak anxiolysis, and most pronounced sedation. Cognitive slowing and thought deceleration are at their strongest. Pain suppression is maximal.
Sedation and cognitive effects gradually diminish. Muscle relaxation persists longer than mental effects. Motor coordination begins to return.
Residual muscular relaxation, mild fatigue, and possible lingering cognitive slowing.
⚠ Avoid driving or operating heavy machinery for up to 12 hours, as residual sedation and motor impairment may persist.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Low
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- GHB · GBL · phenibut
Toxicity
Acute Toxicity
Acute baclofen overdose is a medical emergency. High doses cause profound loss of consciousness, respiratory failure, seizures, and fixed dilated pupils that can mimic brain death.[8][7] Heart rhythm disturbances and dangerously low body temperature also occur.[23]
Full neurological recovery is possible even after presentations that look like brain death. One teenager with no detectable consciousness and fixed pupils recovered completely within two days of supportive care.[8] Recognizing this potential for recovery is critical — premature withdrawal of care must be avoided.
No specific antidote exists. Flumazenil — used to reverse benzodiazepines — does not work for baclofen. Treatment is entirely supportive: airway protection, breathing support, blood pressure management, and seizure control. Dialysis may help patients with kidney impairment but offers little benefit when kidneys function normally.[24][25]
No human lethal dose has been established. The toxic threshold varies widely between individuals. safety citation needed
Toxicity in Kidney Impairment
Impaired kidneys cannot clear baclofen normally, causing the drug to accumulate.[9][19] This has produced brain dysfunction and coma in patients with kidney disease at doses safe for healthy adults. A single standard dose triggered serious brain toxicity in a dialysis patient.[26]
Chronic Toxicity
No specific long-term organ damage has been identified. Baclofen is safe for the liver and has been used in patients with cirrhosis without toxic effects[27] — a significant advantage over most sedative drugs.
Brain Toxicity
Baclofen can produce a metabolic brain disturbance with abnormal electrical patterns on brainwave testing. Combining it with benzodiazepines worsens this beyond simple additive sedation.[28]
Respiratory Effects
Breathing suppression is a risk even at standard doses in susceptible individuals. Central sleep apnea has been documented at doses as low as 10 mg.[29]
Pregnancy
Baclofen is classified FDA Pregnancy Category C. A study of 134 women exposed during early pregnancy found increased risk of major birth defects.[30] Newborns exposed before birth have experienced withdrawal seizures and vital sign instability.[31][32]
Psychological Risks
At therapeutic doses, cognitive fatigue, confusion, and drowsiness are the main psychological effects. Higher doses bring deeper cognitive blunting — amnesia and impaired judgment become more pronounced. Delirium occurs primarily during acute overdose or abrupt withdrawal, and withdrawal-related delirium can be severe.[6]
Depression and suicidal thoughts have been reported in post-marketing surveillance, though separating baclofen's contribution from baseline psychiatric risk in alcohol-dependent populations is difficult. Baclofen does not produce psychedelic-type psychological risks — its profile is that of a sedative, with effects scaling with dose.
Tolerance & Dependence
Abrupt discontinuation of baclofen produces a potentially life-threatening withdrawal syndrome. Baclofen should always be tapered gradually.
Physical dependence develops with regular use.[6] Tolerance to therapeutic effects can appear within days. The withdrawal syndrome includes fever, rapid heart rate, severe agitation, seizures, and delirium — onset can begin within 24 hours of the last dose.[33] This syndrome occurs with both oral and intrathecal forms.[6]
Baclofen rarely produces euphoria or drug craving, giving it lower psychological dependence potential than benzodiazepines.[5] Newborn withdrawal has been documented in infants exposed before birth.[32][31] Cross-tolerance with other GABA-B-active substances is expected based on shared receptor pharmacology.
Drug Interactions
Baclofen's most dangerous interactions are with other central nervous system depressants. Because the drug is barely processed by the liver, enzyme-based interactions are not a significant concern.[9]
- GHB/GBL: Near-additive GABA-B activation produces synergistic sedation and breathing suppression. Classified as a lethal interaction.[34]
- Alcohol: Overlapping GABA pathways combine to suppress breathing at potentially lethal levels.[35] Baclofen is used to reduce alcohol craving, but drinking while taking it compounds sedation dangerously.
- Opioids: Additive breathing suppression through independent mechanisms. Life-threatening episodes have been documented with intrathecal baclofen combined with opioid painkillers.[36]
- Benzodiazepines: These specifically worsen baclofen-related brain toxicity, producing EEG-confirmed metabolic disturbance beyond simple sedation.[28]
- Methaqualone: Additive-to-synergistic sedation via GABA-A and glycine receptor modulation. Classified as a lethal interaction based on pharmacological evidence.
Contraindications
Absolute
- Severe kidney impairment (eGFR <30 mL/min/1.73 m²): Rapid drug accumulation produces brain dysfunction and coma at standard doses.[9][19][26]
Relative
- Moderate kidney impairment: Requires dose reduction and close monitoring.[18]
- Pregnancy: Increased birth defect risk;[30] neonatal withdrawal if used until birth.[31]
- Seizure disorder: Baclofen may lower seizure threshold; seizures occur in both overdose and withdrawal.
- Sleep-disordered breathing: Central sleep apnea documented at 10 mg.[29]
- Concurrent CNS depressant use: Especially opioids,[36] benzodiazepines,[28] GHB/GBL, and alcohol.
- Psychiatric instability: Depression and suicidal ideation reported in post-marketing surveillance.
Harm Reduction[edit]
Forms & Identification
Baclofen circulates almost exclusively as pharmaceutical tablets in 5 mg, 10 mg, 20 mg, and 25 mg strengths. Adulteration is not the primary concern — the main risk is taking the wrong tablet strength, particularly when tablets are obtained without original packaging. Pill identification tools matching imprint codes to manufacturer databases are the most reliable verification method.
Guidelines
- Confirm kidney function before initiating regular use — impaired kidneys dramatically increase toxicity risk at standard doses.
- Start at the lowest available dose (5 mg) and increase gradually over days.
- Never skip doses or stop abruptly after regular use. Taper slowly under medical guidance.
- Avoid driving or operating machinery until individual sedation response is established.
- Keep doses separated by at least 4 hours to prevent accumulation between peaks.
- Do not exceed prescribed doses. High-dose protocols for alcohol use disorder require medical supervision.
- Store tablets in original packaging with clear labeling to prevent dose confusion.
Set & Setting
Dose is the primary variable with baclofen — environment plays a minimal role. Kidney function determines actual drug exposure, and concurrent sedative use compounds risk significantly. Initial doses should be taken in a safe setting where drowsiness and impaired coordination cannot create hazards, particularly avoiding driving or operating machinery.
Aftercare & integration. Baclofen does not produce intense psychological experiences requiring formal integration. Post-use recovery centers on physical recovery — wait for sedation to clear fully before resuming demanding cognitive or physical tasks. For alcohol craving management, anti-craving effects fluctuate through the day due to the short half-life; craving returning between doses is pharmacokinetic, not treatment failure. Stay hydrated and monitor for unusual confusion or drowsiness, which may indicate drug accumulation.
Recovery & Support
Physical dependence on baclofen requires medically supervised tapering to discontinue safely. Abrupt cessation risks life-threatening withdrawal including seizures and delirium. Tapering typically reduces the dose by 5–10 mg every few days, though individual timelines vary with dose magnitude and duration of use.
For individuals using baclofen to manage alcohol dependence, discontinuation should be coordinated with broader addiction treatment. Support resources include addiction medicine specialists, SMART Recovery, and mutual aid groups. Withdrawal management may require inpatient monitoring, particularly at doses above 80 mg/day.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unresponsive or cannot be woken
- Breathing is very slow, shallow, or has stopped
- Seizures
- Fixed, dilated pupils (do not assume brain death — recovery is possible)
- Blue lips or fingertips
- Body temperature dropping noticeably
Immediate steps:
- 1. Call emergency services immediately.
- 2. Place the person in the recovery position if breathing but unconscious.
- 3. Monitor breathing continuously. Begin rescue breathing if it stops.
- 4. Do not induce vomiting.
- 5. Do not administer flumazenil — it does not work for baclofen.
- 6. Keep the person warm — hypothermia is common in overdose.
What to tell the dispatcher:
Substance name (baclofen), estimated amount taken, time of ingestion, and current symptoms. Include any known kidney problems. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents:
No specific antidote exists. Treatment is entirely supportive. Dialysis is generally ineffective in patients with normal kidney function.
Legal Status[edit]
Baclofen is a prescription-only medication in all major jurisdictions and is not classified as a controlled substance anywhere.[5] France is the only country to have approved it specifically for alcohol use disorder.[12][4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Prescription-only; not DEA scheduled | FDA approved 1977 for spasticity (Lioresal). No controlled substance designation. |
| United Kingdom | Prescription-only medicine (POM) | Not controlled under the Misuse of Drugs Act 1971. |
| European Union | Prescription-only (all member states) | France: Baclocur approved for AUD (2020), max 80 mg/day. Other member states: spasticity indication only. |
| France | Prescription-only; AUD indication approved | TRU 2014–2017 (up to 300 mg/day); formal Baclocur authorization June 2020 (80 mg/day cap).[4] |
| Canada | Prescription-only | No controlled substance scheduling. |
| Australia | Prescription-only (TGA approved) | No controlled substance scheduling. |
Legal status varies by jurisdiction and changes over time. This information is not legal advice — verify current status through official sources before relying on it.
references
- [1]
- [2] ^Shaye H, Ishchenko A, Lam JH, et al. (2020) Structural basis of the activation of a metabotropic GABA receptor — Nature doi:10.1038/s41586-020-2408-4
- [3] ^abAmeisen O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician — Alcohol and Alcoholism PMID:15596425
- [4]
- [5] ^abcdLiu J, Wang LN (2019) Baclofen for alcohol withdrawal — Cochrane Database of Systematic Reviews PMID:31689723
- [6] ^abcdIqbal M, Modi P, Sehgal K, et al. (2026) Clinical Presentations and Treatment of Baclofen Toxicity and Withdrawal: A Systematic Review — CNS Drugs PMID:41555041